After spending the last 10-plus years in court, Illumina and BGI Group have reached a $325 million settlement to resolve a number of patent and antitrust claims across the US centered around the companies’ DNA sequencing technology.
Illumina is forking over the $325 million to settle claims following two recent jury decisions in Delaware and California, as well as an antitrust case in California, according to a statement on Thursday from MGI Tech, a BGI affiliate.
As part of the deal, each party will drop any challenges to the California and Delaware jury decisions, and Illumina gets a license to the family of patents that BGI asserted in Delaware.
In 2010, Illumina filed a complaint in California against Complete Genomics, an MGI subsidiary, alleging that the company infringed on three of its DNA sequencing patents with the latter company’s “Complete Genomics Analysis Platform.” In response, Complete Genomics asserted that Illumina had “attempted to achieve monopoly power in genome sequencing technology.”
In a later Delaware case, Complete Genomics accused Illumina of infringing on its own patents with “two-channel” sequencing systems, kits to prepare DNA fragments for sequencing and kits to immobilize, amplify and sequence fragments. The company also filed an anticompetitive suit against Illumina in Delaware last year.
Back in November, a federal jury ruled that four of Illumina’s five patents in the California case were valid, awarding it $8 million, according to a Law360 report. But in May, a Delaware jury decided that Illumina owes Complete Genomics more than $333 million for infringing on two patents, court documents state.
This latest settlement should put an end to the storm of lawsuits — at least for a while. According to MGI’s statement:
“The parties also agree to a three-year period of peace with respect to claims of U.S. patent infringement and violations of any antitrust or unfair competition laws of the United States, during which time they will not sue each other or respective customers in the United States or accrue liability for existing platforms.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Major App Developers Shun Apple’s New Payment Options, Citing Unfavorable Fees
May 12, 2024 by
CPI
Ex-Contractor Pleads Guilty to Rigging Bids in Wildfire Fuel Services for US Forest Service
May 12, 2024 by
CPI
UK Newspapers Warn Apple Against “Web Eraser” Feature’s Threat to Journalism
May 12, 2024 by
CPI
Microsoft Ordered to Pay $242 Million in Patent Infringement Case
May 12, 2024 by
CPI
UK Antitrust Authority Launches Formal Probe into Olink’s Sale to Thermo Fisher
May 12, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI